Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
September 2015, Vol 6, No 8
September 2015, Vol 6, No 8
“Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
By
Alice Goodman
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Boston, MA—Rociletinib, a specially engineered third-generation
EGFR
inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the
T790M
mutation, a heretofore patient population with unmet needs.
T790M
, the most common mutation associated with resistance to first-line
EGFR
-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Read Article
Molecular Signature for Neuroendocrine Prostate Cancer Represents Progress
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations.
Read Article
Oncology News - September 2015
Oncology News
September 2015, Vol 6, No 8
Read Article
FDA News - September 2015
FDA Approvals, News & Updates
September 2015, Vol 6, No 8
Read Article
My Struggle to Understand the Many Definitions of Value
By
Burt Zweigenhaft, PhD, D.Litt
From the Editor
,
Value Peer-spectives
September 2015, Vol 6, No 8
I believe that the dialogue and thoughts being shared and expressed by all cancer care stakeholders is exactly what we need today. Frankly, the conversation has been underground far too long, but the headlines today have been focused solely on the drug cost. Anyone thinking that cancer care costs are going to go down, simply doesn’t understand healthcare economics, because the cost to society will continue to go up over time, with true innovation and value delivered.
Read Article
Transforming Medicine: TMed Will Match People with Life-Threatening Illnesses to Best Treatments, in Real Time
By
Robert Goldberg, PhD
Personalized Medicine
September 2015, Vol 6, No 8
TMed will improve the selection of treatments by adding back and analyzing all the relevant data about the variability of response and the multiplicity of causes…from thousands, if not millions, of patients.
Read Article
Oncology Pipeline Full, and Not Just with Immunotherapies
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Clinicians will soon have more targeted therapies at their disposal, including drugs with novel mechanisms of action.
Read Article
Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer
By
Wayne Kuznar
Prostate Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting.
Read Article
Communication with Oncologists, Not Cost, Tops Patients’ Value Priorities
By
Chase Doyle
Oncologist–Patient Communication
,
Value in Oncology
,
Value Peer-spectives
September 2015, Vol 6, No 8
The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma